<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309359</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0061-C201</org_study_id>
    <secondary_id>2014-003033-26</secondary_id>
    <nct_id>NCT02309359</nct_id>
  </id_info>
  <brief_title>A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of dose regimens of ALX-0061
      administered subcutaneously (s.c.) in combination with methotrexate (MTX) to subjects with
      active rheumatoid arthritis (RA) despite MTX therapy, compared with placebo.

      To assess the effects of ALX-0061 on quality of life, pharmacokinetics (PK), pharmacodynamics
      (PD), and immunogenicity of ALX-0061, and to define the optimal dose regimen for ALX-0061,
      based on safety and efficacy, for further clinical development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who completed the 24-week assessment period and achieved at least 20% improvement in
      swollen joint count (SJC) and/or tender joint count (TJC) at Week 24 of study ALX0061-C201
      were invited to participate in an open-label extension (OLE) study ALX0061-C203
      (NCT02518620), if the study was approved in their country and selection criteria were met.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
The primary endpoint was analyzed using non-responder imputation (NRI), i.e., subjects with missing ACR20 response at Week 12 were treated as non responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With ACR20 Response at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
This endpoint was analyzed using NRI, i.e., subjects with missing response at Week 24 were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With ACR50 Response at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>ACR50 response is defined as:
50% improvement in TJC (68 joints) relative to Week 0 AND
50% improvement in SJC (66 joints) relative to Week 0 AND
50% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With ACR70 Response at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>ACR70 response is defined as:
70% improvement in TJC (68 joints) relative to Week 0 AND
70% improvement in SJC (66 joints) relative to Week 0 AND
70% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With Low Disease Activity (LDA) Using Disease Activity Score 28 (DAS28) Using C-reactive Protein (CRP) at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With LDA Using DAS28 Using Erythrocyte Sedimentation Rate (ESR) at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With LDA Using Simplified Disease Activity Index (SDAI) at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>SDAI = TJC28 + SJC28 + Patient's Global Assessment of Disease Activity (VASPA) + Physician's Global Assessment of Disease Activity (VASPHA) + CRP (mg/dL)
Low disease activity: 3.3 &lt; SDAI ≤ 11.0
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With LDA Using Clinical Disease Activity Index (CDAI) at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>CDAI = TJC28 + SJC28 + VASPA + VASPHA
Low disease activity: 2.8 &lt; CDAI ≤ 10
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With European League Against Rheumatism (EULAR) (CRP) Good Response at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>EULAR good response is defined as an improvement of &gt;1.2 in DAS28 (CRP) relative to baseline.
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects in Remission Using DAS28 (ESR) at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Remission = DAS28(ESR) &lt; 2.6
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects in Remission Using SDAI at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>SDAI = TJC28 + SJC28 + VASPA + VASPHA + CRP (mg/dL)
Remission: SDAI ≤ 3.3
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects in Remission Using CDAI at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>CDAI = TJC28 + SJC28 + VASPA + VASPHA
Remission: CDAI ≤ 2.8
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects in Remission Using Boolean Defined Remission Criteria at Weeks 12 and 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Boolean remission: tender joint count (TJC)28 ≤ 1 and swollen joint count (SJC)28 ≤ 1 and VASPA (cm) ≤ 1 and CRP (mg/dL) ≤ 1
This endpoint was analyzed using non-responder imputation (NRI), i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 12 and 24</measure>
    <time_frame>from baseline till Week 24</time_frame>
    <description>The HAQ-DI is a 20-question instrument which assesses the degree of difficulty the subject had in accomplishing tasks in 8 functional areas over the previous week. The 8 areas are: dressing and grooming, hygiene, arising, reach, eating, grip, walking, common daily activities. Within each area, subjects report the amount of difficulty they have in performing the specific items. There are 4 response options ranging from: 0 = No Difficulty, 1 = With Some Difficulty, 2 = With Much Difficulty, 3 = Unable to Do. The 8 areas are each given a single score equal to the maximum value of their component activities (0, 1, 2, or 3). The sum of the area scores is then divided by the number of areas answered to obtain the final HAQ score (rounded to the nearest value evenly divisible by 0.125). The final HAQ-DI score ranges from 0 to 3. A high score means a high degree of disability (=worse outcome).
Missing values were imputed with the last non-missing observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical Component Score of Short Form Health Survey (SF-36) at Weeks 12 and 24</measure>
    <time_frame>from baseline till Week 24</time_frame>
    <description>The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mental Component Score of Short Form Health Survey (SF-36) at Weeks 12 and 24</measure>
    <time_frame>from baseline till Week 24</time_frame>
    <description>The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Subscale at Weeks 12 and 24</measure>
    <time_frame>from baseline till Week 24</time_frame>
    <description>The FACIT Measurement System is a collection of health-related quality of life questionnaires that assess multidimensional health status in people with various chronic illnesses. The FACIT Fatigue Scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: ALX-0061 Concentration in Serum at Weeks 12 and 24</measure>
    <time_frame>at Week 12 and Week 24 visits</time_frame>
    <description>ALX-0061 concentrations were only measured in samples of subjects randomized to any of the ALX-0061 treatment arms. Samples were taken predose at the concerned visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Concentrations of Soluble Interleukin-6 Receptor (sIL-6R) at Weeks 12 and 24</measure>
    <time_frame>from baseline till Week 24</time_frame>
    <description>Values below the limit of quantification are imputed with the lower limit of quantification (LLOQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Development of a Treatment-emergent Antidrug Antibody Response</measure>
    <time_frame>from baseline till follow-up (FU) (i.e., 12 weeks after last study drug dosing at Week 22 or after early treatment discontinuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With Treatment-emergent Adverse Events by Severity</measure>
    <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-emergent Adverse Events by Severity</measure>
    <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With Treatment-related Treatment-emergent Adverse Events</measure>
    <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-related Treatment-emergent Adverse Events</measure>
    <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo q2w + MTX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 75 mg q4w + MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 150 mg q4w + MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 150 mg q2w + MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 225 mg q2w + MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0061</intervention_name>
    <arm_group_label>ALX-0061 150 mg q2w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 150 mg q4w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 225 mg q2w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 75 mg q4w + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>ALX-0061 150 mg q2w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 150 mg q4w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 75 mg q4w + MTX</arm_group_label>
    <arm_group_label>Placebo q2w + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
    <arm_group_label>ALX-0061 150 mg q2w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 150 mg q4w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 225 mg q2w + MTX</arm_group_label>
    <arm_group_label>ALX-0061 75 mg q4w + MTX</arm_group_label>
    <arm_group_label>Placebo q2w + MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA for at least 6 months prior to screening, and American College of
             Rheumatology (ACR) functional class I-III

          -  Subjects treated with and tolerating MTX

          -  Active RA

          -  Others as defined in the protocol

        Exclusion Criteria:

          -  Have been treated with disease-modifying antirheumatic drugs (DMARDs)/systemic
             immunosuppressives other than MTX.

          -  Have received approved or investigational biological or targeted synthetic DMARD
             therapies for RA less than 6 months prior to screening.

          -  Have a history of toxicity, non-tolerance, primary non-response or inadequate response
             to a biological therapy, or targeted synthetic DMARDs, for RA.

          -  Have received prior therapy blocking the interleukin-6 (IL-6) pathway, at any time.

          -  Others as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ablynx Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Sites</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Sie</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Prague</city>
        <zip>12850</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Zlin</city>
        <zip>76001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Cologne</city>
        <zip>50973</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Budapest</city>
        <zip>1038</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Békéscsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Szikszó</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Székesfehérvar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Culiacan</city>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Merida</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Monclova</city>
        <zip>25714</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Monterey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Monterey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Elblag</city>
        <zip>82300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Katowice</city>
        <zip>40954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Lublin</city>
        <zip>20582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Poznan</city>
        <zip>60773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sochaczew</city>
        <zip>96500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Torun</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02653</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Braila</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bucharest</city>
        <zip>010976</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Oradea</city>
        <zip>410028</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300057</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Novi Sad</city>
        <zip>21112</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 27, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <results_first_submitted>June 12, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <disposition_first_submitted>September 5, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 5, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 6, 2017</disposition_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02309359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 345 subjects were recruited at 63 sites located in Europe (46 sites; 259 subjects), Latin America (7 sites; 59 subjects) and North America (10 sites; 27 subjects). Consent was obtained from the first subject on 30 Jan 2015; the last subject completed the final visit on 8 Aug 2016.</recruitment_details>
      <pre_assignment_details>Of the 712 subjects screened, 367 were screen failures and 345 were randomly assigned to treatment (Intent-to-treat population). All subjects enrolled received study drug and were included in the safety population. All subjects who received at least one dose of ALX-0061 (i.e., 276 subjects) were included in the pharmacokinetic (PK) population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALX-0061 75 mg q4w + MTX</title>
          <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + Methotrexate (MTX; at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="P2">
          <title>ALX-0061 150 mg q4w + MTX</title>
          <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="P3">
          <title>ALX-0061 150 mg q2w + MTX</title>
          <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="P4">
          <title>ALX-0061 225 mg q2w + MTX</title>
          <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="P5">
          <title>Placebo q2w + MTX</title>
          <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALX-0061 75 mg q4w + MTX</title>
          <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="B2">
          <title>ALX-0061 150 mg q4w + MTX</title>
          <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="B3">
          <title>ALX-0061 150 mg q2w + MTX</title>
          <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="B4">
          <title>ALX-0061 225 mg q2w + MTX</title>
          <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="B5">
          <title>Placebo q2w + MTX</title>
          <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="69"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="345"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="10.35"/>
                    <measurement group_id="B2" value="52" spread="13.16"/>
                    <measurement group_id="B3" value="51.9" spread="11.93"/>
                    <measurement group_id="B4" value="52.3" spread="13.36"/>
                    <measurement group_id="B5" value="52.8" spread="11.92"/>
                    <measurement group_id="B6" value="52.4" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 Response at Week 12</title>
        <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
The primary endpoint was analyzed using non-responder imputation (NRI), i.e., subjects with missing ACR20 response at Week 12 were treated as non responders.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 Response at Week 12</title>
          <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
The primary endpoint was analyzed using non-responder imputation (NRI), i.e., subjects with missing ACR20 response at Week 12 were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis of this test was that there is no difference in the percentage of subjects achieving ACR20 response between the treatment groups and the alternative hypothesis was that the percentage of subjects achieving ACR20 response increases with increasing dose level.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Under the assumption of monotonicity, a Cochran-Armitage trend test was performed as the primary efficacy analysis. Data were analyzed according to the intent-to-treat (ITT) principle; thus, subjects were analyzed according to the treatment to which they were assigned. Subjects with missing ACR20 response at Week 12 were treated as non responders (non responder imputation approach).</non_inferiority_desc>
            <p_value>0.172</p_value>
            <method>Cochran-Armitage trend test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With ACR20 Response at Week 24</title>
        <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
This endpoint was analyzed using NRI, i.e., subjects with missing response at Week 24 were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With ACR20 Response at Week 24</title>
          <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
This endpoint was analyzed using NRI, i.e., subjects with missing response at Week 24 were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With ACR50 Response at Weeks 12 and 24</title>
        <description>ACR50 response is defined as:
50% improvement in TJC (68 joints) relative to Week 0 AND
50% improvement in SJC (66 joints) relative to Week 0 AND
50% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With ACR50 Response at Weeks 12 and 24</title>
          <description>ACR50 response is defined as:
50% improvement in TJC (68 joints) relative to Week 0 AND
50% improvement in SJC (66 joints) relative to Week 0 AND
50% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With ACR70 Response at Weeks 12 and 24</title>
        <description>ACR70 response is defined as:
70% improvement in TJC (68 joints) relative to Week 0 AND
70% improvement in SJC (66 joints) relative to Week 0 AND
70% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With ACR70 Response at Weeks 12 and 24</title>
          <description>ACR70 response is defined as:
70% improvement in TJC (68 joints) relative to Week 0 AND
70% improvement in SJC (66 joints) relative to Week 0 AND
70% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With Low Disease Activity (LDA) Using Disease Activity Score 28 (DAS28) Using C-reactive Protein (CRP) at Weeks 12 and 24</title>
        <description>DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Low Disease Activity (LDA) Using Disease Activity Score 28 (DAS28) Using C-reactive Protein (CRP) at Weeks 12 and 24</title>
          <description>DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With LDA Using DAS28 Using Erythrocyte Sedimentation Rate (ESR) at Weeks 12 and 24</title>
        <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With LDA Using DAS28 Using Erythrocyte Sedimentation Rate (ESR) at Weeks 12 and 24</title>
          <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With LDA Using Simplified Disease Activity Index (SDAI) at Weeks 12 and 24</title>
        <description>SDAI = TJC28 + SJC28 + Patient's Global Assessment of Disease Activity (VASPA) + Physician's Global Assessment of Disease Activity (VASPHA) + CRP (mg/dL)
Low disease activity: 3.3 &lt; SDAI ≤ 11.0
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With LDA Using Simplified Disease Activity Index (SDAI) at Weeks 12 and 24</title>
          <description>SDAI = TJC28 + SJC28 + Patient's Global Assessment of Disease Activity (VASPA) + Physician's Global Assessment of Disease Activity (VASPHA) + CRP (mg/dL)
Low disease activity: 3.3 &lt; SDAI ≤ 11.0
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With LDA Using Clinical Disease Activity Index (CDAI) at Weeks 12 and 24</title>
        <description>CDAI = TJC28 + SJC28 + VASPA + VASPHA
Low disease activity: 2.8 &lt; CDAI ≤ 10
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With LDA Using Clinical Disease Activity Index (CDAI) at Weeks 12 and 24</title>
          <description>CDAI = TJC28 + SJC28 + VASPA + VASPHA
Low disease activity: 2.8 &lt; CDAI ≤ 10
Subjects with low disease activity includes subjects who are in remission. This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With European League Against Rheumatism (EULAR) (CRP) Good Response at Weeks 12 and 24</title>
        <description>EULAR good response is defined as an improvement of &gt;1.2 in DAS28 (CRP) relative to baseline.
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With European League Against Rheumatism (EULAR) (CRP) Good Response at Weeks 12 and 24</title>
          <description>EULAR good response is defined as an improvement of &gt;1.2 in DAS28 (CRP) relative to baseline.
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects in Remission Using DAS28 (ESR) at Weeks 12 and 24</title>
        <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Remission = DAS28(ESR) &lt; 2.6
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects in Remission Using DAS28 (ESR) at Weeks 12 and 24</title>
          <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Remission = DAS28(ESR) &lt; 2.6
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects in Remission Using SDAI at Weeks 12 and 24</title>
        <description>SDAI = TJC28 + SJC28 + VASPA + VASPHA + CRP (mg/dL)
Remission: SDAI ≤ 3.3
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects in Remission Using SDAI at Weeks 12 and 24</title>
          <description>SDAI = TJC28 + SJC28 + VASPA + VASPHA + CRP (mg/dL)
Remission: SDAI ≤ 3.3
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects in Remission Using CDAI at Weeks 12 and 24</title>
        <description>CDAI = TJC28 + SJC28 + VASPA + VASPHA
Remission: CDAI ≤ 2.8
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects in Remission Using CDAI at Weeks 12 and 24</title>
          <description>CDAI = TJC28 + SJC28 + VASPA + VASPHA
Remission: CDAI ≤ 2.8
This endpoint was analyzed using NRI, i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects in Remission Using Boolean Defined Remission Criteria at Weeks 12 and 24</title>
        <description>Boolean remission: tender joint count (TJC)28 ≤ 1 and swollen joint count (SJC)28 ≤ 1 and VASPA (cm) ≤ 1 and CRP (mg/dL) ≤ 1
This endpoint was analyzed using non-responder imputation (NRI), i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects in Remission Using Boolean Defined Remission Criteria at Weeks 12 and 24</title>
          <description>Boolean remission: tender joint count (TJC)28 ≤ 1 and swollen joint count (SJC)28 ≤ 1 and VASPA (cm) ≤ 1 and CRP (mg/dL) ≤ 1
This endpoint was analyzed using non-responder imputation (NRI), i.e., subjects with missing response at the concerned visit were treated as non responders.</description>
          <population>Intent-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 12 and 24</title>
        <description>The HAQ-DI is a 20-question instrument which assesses the degree of difficulty the subject had in accomplishing tasks in 8 functional areas over the previous week. The 8 areas are: dressing and grooming, hygiene, arising, reach, eating, grip, walking, common daily activities. Within each area, subjects report the amount of difficulty they have in performing the specific items. There are 4 response options ranging from: 0 = No Difficulty, 1 = With Some Difficulty, 2 = With Much Difficulty, 3 = Unable to Do. The 8 areas are each given a single score equal to the maximum value of their component activities (0, 1, 2, or 3). The sum of the area scores is then divided by the number of areas answered to obtain the final HAQ score (rounded to the nearest value evenly divisible by 0.125). The final HAQ-DI score ranges from 0 to 3. A high score means a high degree of disability (=worse outcome).
Missing values were imputed with the last non-missing observation.</description>
        <time_frame>from baseline till Week 24</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 12 and 24</title>
          <description>The HAQ-DI is a 20-question instrument which assesses the degree of difficulty the subject had in accomplishing tasks in 8 functional areas over the previous week. The 8 areas are: dressing and grooming, hygiene, arising, reach, eating, grip, walking, common daily activities. Within each area, subjects report the amount of difficulty they have in performing the specific items. There are 4 response options ranging from: 0 = No Difficulty, 1 = With Some Difficulty, 2 = With Much Difficulty, 3 = Unable to Do. The 8 areas are each given a single score equal to the maximum value of their component activities (0, 1, 2, or 3). The sum of the area scores is then divided by the number of areas answered to obtain the final HAQ score (rounded to the nearest value evenly divisible by 0.125). The final HAQ-DI score ranges from 0 to 3. A high score means a high degree of disability (=worse outcome).
Missing values were imputed with the last non-missing observation.</description>
          <population>Intent-to-treat population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.696" spread="0.0857"/>
                    <measurement group_id="O2" value="-0.619" spread="0.0657"/>
                    <measurement group_id="O3" value="-0.771" spread="0.0763"/>
                    <measurement group_id="O4" value="-0.615" spread="0.0858"/>
                    <measurement group_id="O5" value="-0.613" spread="0.0718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.0913"/>
                    <measurement group_id="O2" value="-0.665" spread="0.0682"/>
                    <measurement group_id="O3" value="-0.876" spread="0.0802"/>
                    <measurement group_id="O4" value="-0.772" spread="0.0926"/>
                    <measurement group_id="O5" value="-0.662" spread="0.0798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physical Component Score of Short Form Health Survey (SF-36) at Weeks 12 and 24</title>
        <description>The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
        <time_frame>from baseline till Week 24</time_frame>
        <population>Intent-to-treat population; &quot;Number Analyzed&quot; reflect the number of non-missing, non-imputed observations at that specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physical Component Score of Short Form Health Survey (SF-36) at Weeks 12 and 24</title>
          <description>The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
          <population>Intent-to-treat population; &quot;Number Analyzed&quot; reflect the number of non-missing, non-imputed observations at that specific timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.372" spread="0.9136"/>
                    <measurement group_id="O2" value="7.100" spread="0.7477"/>
                    <measurement group_id="O3" value="6.534" spread="0.8878"/>
                    <measurement group_id="O4" value="7.778" spread="0.994"/>
                    <measurement group_id="O5" value="5.413" spread="0.7813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.412" spread="1.0642"/>
                    <measurement group_id="O2" value="8.725" spread="0.9194"/>
                    <measurement group_id="O3" value="8.835" spread="1.009"/>
                    <measurement group_id="O4" value="10.762" spread="1.1497"/>
                    <measurement group_id="O5" value="7.255" spread="0.9483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mental Component Score of Short Form Health Survey (SF-36) at Weeks 12 and 24</title>
        <description>The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
        <time_frame>from baseline till Week 24</time_frame>
        <population>Intent-to-treat population; &quot;Number Analyzed&quot; reflect the number of non-missing, non-imputed observations at that specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mental Component Score of Short Form Health Survey (SF-36) at Weeks 12 and 24</title>
          <description>The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
          <population>Intent-to-treat population; &quot;Number Analyzed&quot; reflect the number of non-missing, non-imputed observations at that specific timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.096" spread="1.4966"/>
                    <measurement group_id="O2" value="7.249" spread="1.1237"/>
                    <measurement group_id="O3" value="9.749" spread="1.4177"/>
                    <measurement group_id="O4" value="5.686" spread="1.6485"/>
                    <measurement group_id="O5" value="5.569" spread="1.6467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.857" spread="1.5326"/>
                    <measurement group_id="O2" value="7.962" spread="1.3932"/>
                    <measurement group_id="O3" value="11.739" spread="1.4159"/>
                    <measurement group_id="O4" value="8.981" spread="1.6876"/>
                    <measurement group_id="O5" value="6.198" spread="1.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Subscale at Weeks 12 and 24</title>
        <description>The FACIT Measurement System is a collection of health-related quality of life questionnaires that assess multidimensional health status in people with various chronic illnesses. The FACIT Fatigue Scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.</description>
        <time_frame>from baseline till Week 24</time_frame>
        <population>Intent-to-treat population; &quot;Number Analyzed&quot; reflect the number of non-missing, non-imputed observations at that specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Subscale at Weeks 12 and 24</title>
          <description>The FACIT Measurement System is a collection of health-related quality of life questionnaires that assess multidimensional health status in people with various chronic illnesses. The FACIT Fatigue Scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.</description>
          <population>Intent-to-treat population; &quot;Number Analyzed&quot; reflect the number of non-missing, non-imputed observations at that specific timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.014" spread="1.3593"/>
                    <measurement group_id="O2" value="8.63" spread="1.0465"/>
                    <measurement group_id="O3" value="10.884" spread="1.5424"/>
                    <measurement group_id="O4" value="9.389" spread="1.3706"/>
                    <measurement group_id="O5" value="6.381" spread="1.2026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.446" spread="1.5687"/>
                    <measurement group_id="O2" value="10.439" spread="1.2157"/>
                    <measurement group_id="O3" value="13.374" spread="1.5621"/>
                    <measurement group_id="O4" value="12.381" spread="1.5193"/>
                    <measurement group_id="O5" value="6.712" spread="1.4651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: ALX-0061 Concentration in Serum at Weeks 12 and 24</title>
        <description>ALX-0061 concentrations were only measured in samples of subjects randomized to any of the ALX-0061 treatment arms. Samples were taken predose at the concerned visits.</description>
        <time_frame>at Week 12 and Week 24 visits</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: ALX-0061 Concentration in Serum at Weeks 12 and 24</title>
          <description>ALX-0061 concentrations were only measured in samples of subjects randomized to any of the ALX-0061 treatment arms. Samples were taken predose at the concerned visits.</description>
          <population>PK population</population>
          <units>micrograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.163" spread="3.7"/>
                    <measurement group_id="O2" value="1.79" spread="3.08"/>
                    <measurement group_id="O3" value="19.9" spread="1.56"/>
                    <measurement group_id="O4" value="32.1" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" spread="2.56"/>
                    <measurement group_id="O2" value="1.64" spread="3.11"/>
                    <measurement group_id="O3" value="20.9" spread="1.5"/>
                    <measurement group_id="O4" value="35.2" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Concentrations of Soluble Interleukin-6 Receptor (sIL-6R) at Weeks 12 and 24</title>
        <description>Values below the limit of quantification are imputed with the lower limit of quantification (LLOQ).</description>
        <time_frame>from baseline till Week 24</time_frame>
        <population>Safety Population; &quot;Number Analyzed&quot; reflect the number of subjects with data available at that specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Concentrations of Soluble Interleukin-6 Receptor (sIL-6R) at Weeks 12 and 24</title>
          <description>Values below the limit of quantification are imputed with the lower limit of quantification (LLOQ).</description>
          <population>Safety Population; &quot;Number Analyzed&quot; reflect the number of subjects with data available at that specific timepoint.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="0.995"/>
                    <measurement group_id="O2" value="29.2" spread="1.04"/>
                    <measurement group_id="O3" value="27.7" spread="0.78"/>
                    <measurement group_id="O4" value="28.9" spread="1.05"/>
                    <measurement group_id="O5" value="28.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="16.7"/>
                    <measurement group_id="O2" value="420" spread="21"/>
                    <measurement group_id="O3" value="519" spread="16.8"/>
                    <measurement group_id="O4" value="488" spread="16.8"/>
                    <measurement group_id="O5" value="52.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" spread="12.9"/>
                    <measurement group_id="O2" value="422" spread="17.8"/>
                    <measurement group_id="O3" value="484" spread="16.3"/>
                    <measurement group_id="O4" value="487" spread="14.3"/>
                    <measurement group_id="O5" value="35.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Development of a Treatment-emergent Antidrug Antibody Response</title>
        <time_frame>from baseline till follow-up (FU) (i.e., 12 weeks after last study drug dosing at Week 22 or after early treatment discontinuation)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O6">
            <title>ALX-0061 Total</title>
            <description>All participants who received ALX-0061</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Development of a Treatment-emergent Antidrug Antibody Response</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With Treatment-emergent Adverse Events by Severity</title>
        <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Treatment-emergent Adverse Events by Severity</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-emergent Adverse Events by Severity</title>
        <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-emergent Adverse Events by Severity</title>
          <population>Safety population</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With Treatment-related Treatment-emergent Adverse Events</title>
        <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Treatment-related Treatment-emergent Adverse Events</title>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-related Treatment-emergent Adverse Events</title>
        <time_frame>From first study drug intake until the Week 24 or Early Termination visit. Only safety data through Week 24 is reported as 256 of the 293 subjects who completed the 24-week treatment period rolled-over to the C203 Study and did not perform the FU visit</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 75 mg q4w + MTX</title>
            <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q4w + MTX</title>
            <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O3">
            <title>ALX-0061 150 mg q2w + MTX</title>
            <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O4">
            <title>ALX-0061 225 mg q2w + MTX</title>
            <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
          <group group_id="O5">
            <title>Placebo q2w + MTX</title>
            <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-related Treatment-emergent Adverse Events</title>
          <population>Safety population</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first study drug intake up to and including follow-up, i.e., maximum of 34 weeks (22 weeks of treatment + 12 weeks of follow-up).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ALX-0061 75 mg q4w + MTX</title>
          <description>ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="E2">
          <title>ALX-0061 150 mg q4w + MTX</title>
          <description>ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="E3">
          <title>ALX-0061 150 mg q2w + MTX</title>
          <description>ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
ALX-0061
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="E4">
          <title>ALX-0061 225 mg q2w + MTX</title>
          <description>ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
The last study drug administration was at the Week 22 visit.
ALX-0061
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
        <group group_id="E5">
          <title>Placebo q2w + MTX</title>
          <description>Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
Placebo
Methotrexate: Stable background dose of commercially available methotrexate (not provided by the Sponsor).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of any results from this study will be according to the principles of the Declaration of Helsinki, and will require prior review and written agreement of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Ablynx NV</organization>
      <phone>+32 (0)9 262 00 00</phone>
      <email>clinicaltrials@ablynx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

